Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Yongfu
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis	Completed	2	140	RoW	Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group	Tianjin Hemay Pharmaceutical Co., Ltd	Rheumatoid Arthritis	06/23	06/23
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis	Recruiting	2	261	RoW	Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005）	Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH	Ankylosing Spondylitis	02/25	10/25
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Oct 2024 - Dec 2024 : Data for SLE Jul 2024 - Sep 2024 : Data for CLE	Completed	2	456	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE	Recruiting	2	532	Europe, Japan, US, RoW	M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA	Systemic Lupus Erythematosus	04/25	04/25